The two companies will work together to deliver a seamless service offering for clients from discovery to manufacturing and PoC preclinical and phase I & II design and execution.
Fusion Antibodies are working with a number of clients on pilot projects for their latest technology – RAMP™ – Rational Affinity Maturation Platform.
Why investing in pre-clinical activity is crucial to maximise the chance of success in clinical trials.
Fusion Antibodies has been granted approval to participate in the Crédit Impôt Recherche (CIR) scheme, meaning our French clients can enjoy a significant tax break by partnering with us for pre-clinical antibody research.
Fusion Antibodies, a world leading CRO, has today announced that they have successfully completed their 150th Antibody Humanization project as part of their Antibody Engineering offering
Fusion Antibodies are pleased to be attending Antibody Engineering & Therapeutics Asia on 26-28th February 2019 in Tokyo.
